Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904241 · ClinicalTrials.gov registry record
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
A clinical trial of Ganglioneuroblastoma and Localized Resectable Neuroblastoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- 10,000
- Enrollment target
- 20
- Study locations
NCT00904241: Active study of Ganglioneuroblastoma and Localized Resectable Neuroblastoma, sponsored by Children's Oncology Group.
NCT00904241 is a study of Ganglioneuroblastoma and Localized Resectable Neuroblastoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 10,000 participants, above the 213-participant average among 8 other Ganglioneuroblastoma trials with a reported enrollment target (4595% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904241, a study of Ganglioneuroblastoma and Localized Resectable Neuroblastoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Primary Outcome
Life tables, Kaplan-Meier survival curves, log-rank tests, and Cox regression will be used to explore the relationship of laboratory variables to outcome.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda University Medical Center - Loma Linda
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Mattel Children's Hospital UCLA - Los Angeles
- Valley Children's Hospital - Madera
- Children's Hospital and Research Center at Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
- USA Health Strada Patient Care Center - Mobile
Arizona
- Cardon Children's Medical Center - Mesa
- Phoenix Childrens Hospital - Phoenix
- The University of Arizona Medical Center-University Campus - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Alaska
- Providence Alaska Medical Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2000-11-06 |
What the registry record for NCT00904241 still lists
NCT00904241 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 213-participant average among 8 other Ganglioneuroblastoma trials with a reported enrollment target (4595% higher).
The record links to 6 conditions, with Ganglioneuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00904241 names 20 study sites across 5 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00904241 about?
NCT00904241 is a clinical study titled "Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma". This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
What is the current status of trial NCT00904241?
This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2000-11-06.
What conditions does trial NCT00904241 study?
This clinical trial studies the following conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Stage 4 Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma.
What interventions are being tested in trial NCT00904241?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT00904241?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904241 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ganglioneuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00904241's enrollment target sits among peer trials
10,000 1st of 8 higher than 8 of 8 other Ganglioneuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ganglioneuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RECRUITING · Phase 3
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
ACTIVE NOT RECRUITING · Phase 1
-
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI